{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:16:35Z","timestamp":1778681795246,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s11938-005-0011-2","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T14:42:27Z","timestamp":1180881747000},"page":"187-196","source":"Crossref","is-referenced-by-count":25,"title":["Infliximab: Use in inflammatory bowel disease"],"prefix":"10.1007","volume":"8","author":[{"given":"Win J.","family":"Travassos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"Cheifetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","volume":"347","author":"DK Podolsky","year":"2002","unstructured":"Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002, 347: 417\u2013429.","journal-title":"N Engl J Med"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMp048253","volume":"351","author":"F Cominelli","year":"2004","unstructured":"Cominelli F: Cytokine-based therapies for Crohn\u2019s disease-new paradigms. N Engl J Med 2004, 351: 2045\u20132048.","journal-title":"N Engl J Med"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","volume":"40","author":"S Deventer van","year":"1997","unstructured":"van Deventer S: Tumour Necrosis Factor and Crohn\u2019s Disease. Gut 1997, 40: 443\u2013448.","journal-title":"Gut"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.gtc.2004.02.014","volume":"33","author":"LW Comerford","year":"2004","unstructured":"Comerford LW, Bickston SJ: Treatment of luminal and fistulizing Crohn\u2019s disease with infliximab. Gastroenterol Clin North Am 2004, 33: 387\u2013406.","journal-title":"Gastroenterol Clin North Am"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","volume":"106","author":"EJ Breese","year":"1994","unstructured":"Breese EJ, Michie CA, Nicholls SW: Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994, 106: 1455\u20131466.","journal-title":"Gastroenterology"},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","volume":"339","author":"CP Braegger","year":"1992","unstructured":"Braegger CP, Nicholls S, Murch SH, et al.: Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992, 339: 89\u201391.","journal-title":"Lancet"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.gtc.2004.02.007","volume":"33","author":"GI Papachristou","year":"2004","unstructured":"Papachristou GI, Plevy S: Novel Biologics in inflammatory bowel disease. Gastroenterol Clin North Am 2004, 33: 251\u2013269.","journal-title":"Gastroenterol Clin North Am"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/cyto.1995.1003","volume":"7","author":"SA Siegel","year":"1995","unstructured":"Siegel SA, Shealy DJ, Nakada MT, et al.: The mouse\/ human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995, 7: 15\u201325.","journal-title":"Cytokine"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","volume":"7","author":"BJ Scallon","year":"1995","unstructured":"Scallon BJ, Moore MA, Trinh H, et al.: Chimeric anti-TNF-monoclonal antibody cA2 binds recombinant transmembrane TNF-a and activates immune effector functions. Cytokine 1995, 7: 251\u2013259.","journal-title":"Cytokine"},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","volume":"121","author":"A L\u00fcgering","year":"2001","unstructured":"L\u00fcgering A, Schmidt M, L\u00fcgering N, et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspasedependent pathway. Gastroenterology 2001, 121: 1145\u20131157.","journal-title":"Gastroenterology"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","volume":"50","author":"T Hove Ten","year":"2002","unstructured":"Ten Hove T, van Montfrans C, Peppelenbosch MP, et al.: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease. Gut 2002, 50: 206\u2013211.","journal-title":"Gut"},{"key":"11_CR12","unstructured":"Remicade (Infliximab) current prescribing information."},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn\u2019s disease. N Engl J Med 1997, 337: 1029\u20131035. This groundbreaking study demonstrated effectiveness of a single dose of Infliximab in moderate to severe Crohn\u2019s disease refractory to conventional treatment.","journal-title":"N Engl J Med"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance Infliximab for Crohn\u2019s Disease: the ACCENT I Randomised Trial. Lancet 2002, 359: 1541\u20131549. This study established the utility of Infliximab as maintenance treatment for moderate to severe Crohn\u2019s disease refractory to conventional treatment.","journal-title":"Lancet"},{"key":"11_CR15","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 1999, 340: 1398\u20131405. This study established the effectiveness of Infliximab in treating fistulizing Crohn\u2019s disease.","journal-title":"N Engl J Med"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med 2004, 350: 876\u2013885. This study (ACCENT II) established the effectiveness of Infliximab as maintenance therapy for fistulizing Crohn\u2019s disease.","journal-title":"N Engl J Med"},{"key":"11_CR17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","volume":"2","author":"BE Sands","year":"2004","unstructured":"Sands BE, Blank MA, Patel K, et al.: Long-term treatment of rectovaginal fistulas in Crohn\u2019s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004, 2: 912\u2013920.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of Infliximab in Crohn\u2019s disease. Gastroenterology 2004, 126: 402\u2013413.","journal-title":"Gastroenterology"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with Infliximab: A randomised controlled multicentre trial. Lancet 2002, 359: 1187\u20131193.","journal-title":"Lancet"},{"key":"11_CR20","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/ard.2003.012450","volume":"63","author":"S Generini","year":"2004","unstructured":"Generini S, Giacomelli R, Fedi R, et al.: Infliximab in spondyloarthropathy associated with Crohn\u2019s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004, 63: 1664\u20131669.","journal-title":"Ann Rheum Dis"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2036.2004.02055.x","volume":"20","author":"FT Veloso","year":"2004","unstructured":"Veloso FT: Skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20: 50\u201353.","journal-title":"Aliment Pharmacol Ther"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archsurg.135.5.564","volume":"135","author":"DG Sheldon","year":"2000","unstructured":"Sheldon DG, Sawchuk LL, Kozarek RA, et al.: Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000, 135: 564\u2013568.","journal-title":"Arch Surg"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1572-0241.2002.05514.x","volume":"97","author":"W Fries","year":"2002","unstructured":"Fries W, Giofre MR, Catanoso M, et al.: Treatment of acute uveitis associated with Crohn\u2019s disease and sacroileitis with infliximab. Am J Gastroenterol 2002, 97: 499\u2013500.","journal-title":"Am J Gastroenterol"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, et al.: Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004, 51: 534\u2013542.","journal-title":"J Am Acad Dermatol"},{"key":"11_CR25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2004.02.070","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126: 1593\u20131610. Superb review article summarizing the most up-to-date perspectives on Infliximab.","journal-title":"Gastroenterology"},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/j.1572-0241.2001.04039.x","volume":"96","author":"WY Chey","year":"2001","unstructured":"Chey WY, Hussain A, Ryan C, et al.: Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001, 96: 2373\u20132381.","journal-title":"Am J Gastroenterol"},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.gtc.2004.02.005","volume":"33","author":"JC Chang","year":"2004","unstructured":"Chang JC, Cohen RD: Medical management of severe ulcerative colitis. Gastroenterol Clin North Am 2004, 33: 235\u2013250.","journal-title":"Gastroenterol Clin North Am"},{"issue":"Suppl 1","key":"11_CR28","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ibd.3780070507","volume":"7","author":"WY Chey","year":"2001","unstructured":"Chey WY: Infliximab for patients with refractory ulcerative colitis. Inflammatory Bowel Dis 2001, 7(Suppl 1): S30-S33.","journal-title":"Inflammatory Bowel Dis"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/j.1572-0241.2002.06026.x","volume":"97","author":"C Su","year":"2002","unstructured":"Su C, Salzberg BA, Lewis JD, et al.: Efficacy of antitumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002, 97: 2577\u20132584.","journal-title":"Am J Gastroenterol"},{"key":"11_CR30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/00042737-200411000-00014","volume":"16","author":"T Ochsenkuhn","year":"2004","unstructured":"Ochsenkuhn T, Sackmann M, Goke B: Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004, 16: 1167\u20131171.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","volume":"7","author":"BE Sands","year":"2001","unstructured":"Sands BE, Tremaine WJ, Sandborn WJ, et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflammatory Bowel Dis 2001, 7: 83\u201388.","journal-title":"Inflammatory Bowel Dis"},{"key":"11_CR32","first-page":"A","volume":"122","author":"CJ Probert","year":"2002","unstructured":"Probert CJ, Hearing SD, Schreiber S, et al.: Infliximab in steroid-resistant ulcerative colitis: A randomized controlled trial. Gastroenterology 2002, 122: A-99.","journal-title":"Gastroenterology"},{"key":"11_CR33","unstructured":"Centocor: http:\/\/www.centocor.com\/cgi-bin\/site\/ media\/media_news.cgi?news_id=74. Accessed January 10, 2005."},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/gast.2002.35390","volume":"123","author":"MA Parsi","year":"2002","unstructured":"Parsi MA, Achkar JP, Richardson S, et al.: Predictors of response to Infliximab in patients with Crohn\u2019s disease. Gastroenterology 2002, 123: 707\u2013713.","journal-title":"Gastroenterology"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"P Rutgeerts","year":"1999","unstructured":"Rutgeerts P, D\u2019Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease. Gastroenterology 1999, 117: 761\u2013769.","journal-title":"Gastroenterology"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","volume":"98","author":"A Cheifetz","year":"2003","unstructured":"Cheifetz A, Smedley M, Martin S, et al.: The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003, 98: 1315\u20131324.","journal-title":"Am J Gastroenterol"},{"key":"11_CR37","doi-asserted-by":"crossref","unstructured":"Chung ES, Packer M, Lo KH, et al.: Randomized, double-blind, placebo-controlled, pilot trial of Infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-tosevere heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial circulation 2003, 107:3133\u20133140.","DOI":"10.1161\/01.CIR.0000077913.60364.D2"},{"key":"11_CR38","unstructured":"Kineret (Anakinra) current prescribing information."},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200464160-00004","volume":"64","author":"PD Han","year":"2004","unstructured":"Han PD, Cohen RD: Managing immunogenic responses to infliximab: treatment implications for patients with Crohn\u2019s disease. Drugs 2004, 64: 1767\u20131777.","journal-title":"Drugs"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1111\/j.1572-0241.2002.07093.x","volume":"97","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn WJ, Hanauer SB: Infliximab in the treatment of Crohn\u2019s Disease: a user\u2019s guide for clinicians. Am J Gastroenterol 2002, 97: 2962\u20132972. Excellent review article with brief summaries of relevant literature for the clinician.","journal-title":"Am J Gastroenterol"},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Wagner CL, Bala M, et al.: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease. Clin Gastroenterol Hepatol 2004, 2: 542\u2013553.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn\u2019s disease. N Engl J Med 2003, 348: 601\u2013608.","journal-title":"N Engl J Med"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","volume":"124","author":"RJ Farrell","year":"2003","unstructured":"Farrell RJ, Alsahli M, Yoon-Tae J, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial. Gastroenterol 2003, 124: 917\u2013924.","journal-title":"Gastroenterol"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"J-F Colombel","year":"2004","unstructured":"Colombel J-F, Loftus EV, Tremaine WJ, et al.: The safety profile of Infliximab in patients with Crohn\u2019s disease: The Mayo Clinic experience in 500 patients. Gastroenterology 2004, 126: 19\u201331.","journal-title":"Gastroenterology"},{"key":"11_CR45","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with Infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001, 345: 1098\u20131104.","journal-title":"N Engl J Med"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","volume":"2","author":"WS Mow","year":"2004","unstructured":"Mow WS, Abreu-Martin MT, Papadakis KA, et al.: High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatology 2004, 2: 309\u2013313.","journal-title":"Clin Gastroenterol Hepatology"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44: 2962\u20132869.","journal-title":"Arthritis Rheum"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00054725-200401000-00004","volume":"10","author":"CW Thomas","year":"2004","unstructured":"Thomas CW, Weinshenker BG, Sandborn WJ: Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn\u2019s disease. Inflamm Bowel Dis 2004, 10: 28\u201331.","journal-title":"Inflamm Bowel Dis"},{"key":"11_CR49","unstructured":"Emedicine (Multiple Sclerosis): http:\/\/www.emedicine.com\/radio\/topic461.htm."},{"key":"11_CR50","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1590-8658(03)00448-1","volume":"35","author":"P Sarzi-Puttini","year":"2003","unstructured":"Sarzi-Puttini P, Ardizzone S, Manzionna G, et al.: Infliximab-induced lupus in Crohn\u2019s disease: a case report. Dig Liver Dis 2003, 35: 814\u2013817.","journal-title":"Dig Liver Dis"},{"key":"11_CR51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","volume":"125","author":"S Vermeire","year":"2003","unstructured":"Vermeire S, Noman M, Van Assche G, et al.: Autoimmunity associated with anti-tumor necrosis factoralpha treatment in Crohn\u2019s disease: A prospective cohort study. Gastroenterology 2003, 125: 32\u201339.","journal-title":"Gastroenterology"},{"key":"11_CR52","unstructured":"U.S. Food and Drug Administration: http:\/\/www.fda.gov\/medwatch\/SAFETY\/2004\/ remicade_DHCP_dec04.pdf. Accessed January 10, 2005."},{"key":"11_CR53","unstructured":"TREAT registry; data from Centocor as of 6\/7\/04."},{"key":"11_CR54","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","volume":"99","author":"JA Katz","year":"2004","unstructured":"Katz JA, Antoni C, Keenan GF, et al.: Outcome of pregnancy in women receiving Infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis. Am J Gastro 2004, 99: 2385\u20132392.","journal-title":"Am J Gastro"},{"key":"11_CR55","unstructured":"U.S. National Library of Medicine: http:\/\/www.nlm.nih.gov\/medlineplus\/druginfo\/uspdi\/ 203667.html. Accessed January 10, 2005."},{"key":"11_CR56","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1572-0241.2000.01779.x","volume":"9","author":"RD Cohen","year":"2000","unstructured":"Cohen RD, Larson LR, Roth JM, et al.: The cost of hospitalization in Crohn\u2019s disease. Am J Gastroenterol 2000, 9: 524\u2013530.","journal-title":"Am J Gastroenterol"},{"key":"11_CR57","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1572-0241.2000.02261.x","volume":"95","author":"BG Feagan","year":"2000","unstructured":"Feagan BG, Vreeland MG, Larson LR, et al.: Annual cost of care for Crohn\u2019s disease: a payor\u2019s perspective. Am J Gastroenterol 2000, 95: 1955\u20131960.","journal-title":"Am J Gastroenterol"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-005-0011-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-005-0011-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-005-0011-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:57:01Z","timestamp":1559437021000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-005-0011-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11938-005-0011-2","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}